stockrow
Friday 6 November 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Revenue
- +25.2%
- EPS
- +25.0%
- Free cash flow
- +72.2%
- Total debt
- +2.40%
Quarter to September 2026, against a year earlier
10.04
0.28
+2.87%
Follow SGHT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 5 | 4 |
| (50.74%) | (56.64%) | (48.42%) | (50.07%) | ||
| (29.77%) | (31.12%) | (26.24%) | (25.68%) | ||
ROIC |
(188.86%) | (235.20%) | (125.18%) | (127.79%) | |
Return on Tangible Assets |
(37.19%) | (41.41%) | (36.02%) | (34.20%) | |
Average Days of Receivables |
45.98 | 48.61 | 49.84 | 55.25 | |
Free Cash Flow per Share |
(0.58) | (0.47) | (0.43) | (0.31) | |
Free Cash Flow |
(30.05) | (25.40) | (23.33) | (16.91) | |
Capital Expenditures |
(0.36) | (0.28) | (0.09) | 0.01 | |
| Other line items | |||||
Cash ROIC |
(15.32%) | (14.16%) | (13.45%) | (10.09%) | |
Accounts Receivable Turnover |
7.54 | 7.95 | 7.94 | 7.65 | |
Accounts Payable Turnover |
7.05 | 5.18 | 5.05 | 4.79 | |
Inventory Turnover |
1.52 | 1.72 | 1.69 | 1.50 | |
Average Days of Payables |
45.83 | 49.29 | 69.00 | 93.73 | |
Days of Inventory on Hand |
265.02 | 232.44 | 207.04 | 219.05 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.88% | 15.99% | 13.01% | 11.54% | |
Selling, General and Administrative Expense of Revenue |
115.25% | 114.99% | 108.38% | 105.73% | |
Share Based Compensation of Revenue |
16.87% | 14.66% | 12.94% | 12.78% | |
Interest Coverage |
(7.21) | (6.93) | (5.41) | (5.06) | |
Operating CF/Net income |
0.77 | 0.67 | 0.78 | 0.60 | |
Depreciation/Fixed assets |
0.89 | 0.86 | 0.82 | 0.80 | |
Capex/Depreciation |
(0.25) | (0.20) | (0.07) | 0.01 | |
Revenue per Share |
1.48 | 1.47 | 1.53 | 1.60 | |
Operating CF per Share |
(0.57) | (0.47) | (0.43) | (0.31) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026